Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Buy
58
ALLO Quote, Financials, Valuation and Earnings
Last price:
$1.45
Seasonality move
:
-16.51%
Day range:
$1.41 - $1.51
52-week range:
$0.86 - $3.78
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2,442.58x
P/B ratio:
1.03x
Volume:
1.5M
Avg. volume:
2.3M
1-year change:
-36.14%
Market cap:
$323.6M
Revenue:
$22K
EPS (TTM):
-$0.98
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ALLO
Allogene Therapeutics, Inc.
|
$1.8K | -$0.23 | -92.41% | -21.56% | $7.56 |
|
ADPT
Adaptive Biotechnologies Corp.
|
$64.6M | -$0.14 | 24.92% | -21.12% | $20.29 |
|
AIM
AIM ImmunoTech
|
-- | -$0.09 | -23.08% | -53.85% | $4.50 |
|
AKRO
Akero Therapeutics, Inc.
|
-- | -$0.93 | -- | -0.63% | $56.00 |
|
ANIP
ANI Pharmaceuticals, Inc.
|
$212.9M | $1.77 | 22% | 68.6% | $109.88 |
|
PLX
Protalix Biotherapeutics, Inc.
|
$17.9M | -- | -7.76% | -- | $11.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ALLO
Allogene Therapeutics, Inc.
|
$1.44 | $7.56 | $323.6M | -- | $0.00 | 0% | 2,442.58x |
|
ADPT
Adaptive Biotechnologies Corp.
|
$17.46 | $20.29 | $2.7B | -- | $0.00 | 0% | 10.57x |
|
AIM
AIM ImmunoTech
|
$0.04 | $4.50 | $2.8M | -- | $0.00 | 0% | 13.27x |
|
AKRO
Akero Therapeutics, Inc.
|
$54.63 | $56.00 | $4.5B | -- | $0.00 | 0% | -- |
|
ANIP
ANI Pharmaceuticals, Inc.
|
$82.74 | $109.88 | $1.9B | 50.74x | $0.00 | 0% | 2.02x |
|
PLX
Protalix Biotherapeutics, Inc.
|
$1.75 | $11.00 | $140.7M | 25.18x | $0.00 | 0% | 2.23x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ALLO
Allogene Therapeutics, Inc.
|
21.26% | -0.074 | 30.77% | 7.92x |
|
ADPT
Adaptive Biotechnologies Corp.
|
51.1% | 3.094 | 9.36% | 3.09x |
|
AIM
AIM ImmunoTech
|
48.41% | 0.745 | 17.25% | 0.71x |
|
AKRO
Akero Therapeutics, Inc.
|
0.12% | 3.225 | 0.03% | 15.48x |
|
ANIP
ANI Pharmaceuticals, Inc.
|
55.53% | -0.550 | 30.7% | 2.40x |
|
PLX
Protalix Biotherapeutics, Inc.
|
13.39% | -1.718 | 4.58% | 2.00x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ALLO
Allogene Therapeutics, Inc.
|
-$3.1M | -$44.9M | -44.62% | -54.89% | -315927.27% | -$29.9M |
|
ADPT
Adaptive Biotechnologies Corp.
|
$72.6M | $10.3M | -18.96% | -39.8% | 10.95% | -$7.5M |
|
AIM
AIM ImmunoTech
|
$27K | -$4.5M | -219.06% | -256.33% | -9994.29% | -$3.3M |
|
AKRO
Akero Therapeutics, Inc.
|
-- | -$90.2M | -31.13% | -32.14% | -- | -$67.2M |
|
ANIP
ANI Pharmaceuticals, Inc.
|
$111.8M | $22.8M | 3.31% | 8.22% | 10.02% | $37.9M |
|
PLX
Protalix Biotherapeutics, Inc.
|
$9.5M | $2.1M | 10.63% | 12.06% | 11.94% | -$4.2M |
Allogene Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns ALLO or ADPT?
Adaptive Biotechnologies Corp. has a net margin of -295454.55% compared to Allogene Therapeutics, Inc.'s net margin of 10.16%. Allogene Therapeutics, Inc.'s return on equity of -54.89% beat Adaptive Biotechnologies Corp.'s return on equity of -39.8%.
Company Gross Margin Earnings Per Share Invested Capital ALLOAllogene Therapeutics, Inc.-- -$0.19 $400.5M ADPTAdaptive Biotechnologies Corp.77.3% $0.06 $417.9M -
What do Analysts Say About ALLO or ADPT?
Allogene Therapeutics, Inc. has a consensus price target of $7.56, signalling upside risk potential of 425%. On the other hand Adaptive Biotechnologies Corp. has an analysts' consensus of $20.29 which suggests that it could grow by 16.18%. Given that Allogene Therapeutics, Inc. has higher upside potential than Adaptive Biotechnologies Corp., analysts believe Allogene Therapeutics, Inc. is more attractive than Adaptive Biotechnologies Corp..
Company Buy Ratings Hold Ratings Sell Ratings ALLOAllogene Therapeutics, Inc.9 2 0 ADPTAdaptive Biotechnologies Corp.5 1 0 -
Is ALLO or ADPT More Risky?
Allogene Therapeutics, Inc. has a beta of 0.471, which suggesting that the stock is 52.924% less volatile than S&P 500. In comparison Adaptive Biotechnologies Corp. has a beta of 2.201, suggesting its more volatile than the S&P 500 by 120.134%.
-
Which is a Better Dividend Stock ALLO or ADPT?
Allogene Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Adaptive Biotechnologies Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Allogene Therapeutics, Inc. pays -- of its earnings as a dividend. Adaptive Biotechnologies Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ALLO or ADPT?
Allogene Therapeutics, Inc. quarterly revenues are --, which are smaller than Adaptive Biotechnologies Corp. quarterly revenues of $94M. Allogene Therapeutics, Inc.'s net income of -$41.4M is lower than Adaptive Biotechnologies Corp.'s net income of $9.5M. Notably, Allogene Therapeutics, Inc.'s price-to-earnings ratio is -- while Adaptive Biotechnologies Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Allogene Therapeutics, Inc. is 2,442.58x versus 10.57x for Adaptive Biotechnologies Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ALLOAllogene Therapeutics, Inc.2,442.58x -- -- -$41.4M ADPTAdaptive Biotechnologies Corp.10.57x -- $94M $9.5M
-
Which has Higher Returns ALLO or AIM?
AIM ImmunoTech has a net margin of -295454.55% compared to Allogene Therapeutics, Inc.'s net margin of -10571.43%. Allogene Therapeutics, Inc.'s return on equity of -54.89% beat AIM ImmunoTech's return on equity of -256.33%.
Company Gross Margin Earnings Per Share Invested Capital ALLOAllogene Therapeutics, Inc.-- -$0.19 $400.5M AIMAIM ImmunoTech77.14% -$0.06 $5.6M -
What do Analysts Say About ALLO or AIM?
Allogene Therapeutics, Inc. has a consensus price target of $7.56, signalling upside risk potential of 425%. On the other hand AIM ImmunoTech has an analysts' consensus of $4.50 which suggests that it could grow by 11066.25%. Given that AIM ImmunoTech has higher upside potential than Allogene Therapeutics, Inc., analysts believe AIM ImmunoTech is more attractive than Allogene Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ALLOAllogene Therapeutics, Inc.9 2 0 AIMAIM ImmunoTech1 0 0 -
Is ALLO or AIM More Risky?
Allogene Therapeutics, Inc. has a beta of 0.471, which suggesting that the stock is 52.924% less volatile than S&P 500. In comparison AIM ImmunoTech has a beta of 0.760, suggesting its less volatile than the S&P 500 by 23.953%.
-
Which is a Better Dividend Stock ALLO or AIM?
Allogene Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AIM ImmunoTech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Allogene Therapeutics, Inc. pays -- of its earnings as a dividend. AIM ImmunoTech pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ALLO or AIM?
Allogene Therapeutics, Inc. quarterly revenues are --, which are smaller than AIM ImmunoTech quarterly revenues of $35K. Allogene Therapeutics, Inc.'s net income of -$41.4M is lower than AIM ImmunoTech's net income of -$3.7M. Notably, Allogene Therapeutics, Inc.'s price-to-earnings ratio is -- while AIM ImmunoTech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Allogene Therapeutics, Inc. is 2,442.58x versus 13.27x for AIM ImmunoTech. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ALLOAllogene Therapeutics, Inc.2,442.58x -- -- -$41.4M AIMAIM ImmunoTech13.27x -- $35K -$3.7M
-
Which has Higher Returns ALLO or AKRO?
Akero Therapeutics, Inc. has a net margin of -295454.55% compared to Allogene Therapeutics, Inc.'s net margin of --. Allogene Therapeutics, Inc.'s return on equity of -54.89% beat Akero Therapeutics, Inc.'s return on equity of -32.14%.
Company Gross Margin Earnings Per Share Invested Capital ALLOAllogene Therapeutics, Inc.-- -$0.19 $400.5M AKROAkero Therapeutics, Inc.-- -$0.99 $958.8M -
What do Analysts Say About ALLO or AKRO?
Allogene Therapeutics, Inc. has a consensus price target of $7.56, signalling upside risk potential of 425%. On the other hand Akero Therapeutics, Inc. has an analysts' consensus of $56.00 which suggests that it could grow by 2.51%. Given that Allogene Therapeutics, Inc. has higher upside potential than Akero Therapeutics, Inc., analysts believe Allogene Therapeutics, Inc. is more attractive than Akero Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ALLOAllogene Therapeutics, Inc.9 2 0 AKROAkero Therapeutics, Inc.1 6 0 -
Is ALLO or AKRO More Risky?
Allogene Therapeutics, Inc. has a beta of 0.471, which suggesting that the stock is 52.924% less volatile than S&P 500. In comparison Akero Therapeutics, Inc. has a beta of -0.399, suggesting its less volatile than the S&P 500 by 139.855%.
-
Which is a Better Dividend Stock ALLO or AKRO?
Allogene Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Akero Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Allogene Therapeutics, Inc. pays -- of its earnings as a dividend. Akero Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ALLO or AKRO?
Allogene Therapeutics, Inc. quarterly revenues are --, which are smaller than Akero Therapeutics, Inc. quarterly revenues of --. Allogene Therapeutics, Inc.'s net income of -$41.4M is higher than Akero Therapeutics, Inc.'s net income of -$81.6M. Notably, Allogene Therapeutics, Inc.'s price-to-earnings ratio is -- while Akero Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Allogene Therapeutics, Inc. is 2,442.58x versus -- for Akero Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ALLOAllogene Therapeutics, Inc.2,442.58x -- -- -$41.4M AKROAkero Therapeutics, Inc.-- -- -- -$81.6M
-
Which has Higher Returns ALLO or ANIP?
ANI Pharmaceuticals, Inc. has a net margin of -295454.55% compared to Allogene Therapeutics, Inc.'s net margin of 10.59%. Allogene Therapeutics, Inc.'s return on equity of -54.89% beat ANI Pharmaceuticals, Inc.'s return on equity of 8.22%.
Company Gross Margin Earnings Per Share Invested Capital ALLOAllogene Therapeutics, Inc.-- -$0.19 $400.5M ANIPANI Pharmaceuticals, Inc.49.07% $1.13 $1.1B -
What do Analysts Say About ALLO or ANIP?
Allogene Therapeutics, Inc. has a consensus price target of $7.56, signalling upside risk potential of 425%. On the other hand ANI Pharmaceuticals, Inc. has an analysts' consensus of $109.88 which suggests that it could grow by 32.8%. Given that Allogene Therapeutics, Inc. has higher upside potential than ANI Pharmaceuticals, Inc., analysts believe Allogene Therapeutics, Inc. is more attractive than ANI Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ALLOAllogene Therapeutics, Inc.9 2 0 ANIPANI Pharmaceuticals, Inc.4 1 0 -
Is ALLO or ANIP More Risky?
Allogene Therapeutics, Inc. has a beta of 0.471, which suggesting that the stock is 52.924% less volatile than S&P 500. In comparison ANI Pharmaceuticals, Inc. has a beta of 0.484, suggesting its less volatile than the S&P 500 by 51.639%.
-
Which is a Better Dividend Stock ALLO or ANIP?
Allogene Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ANI Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Allogene Therapeutics, Inc. pays -- of its earnings as a dividend. ANI Pharmaceuticals, Inc. pays out 8.77% of its earnings as a dividend. ANI Pharmaceuticals, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ALLO or ANIP?
Allogene Therapeutics, Inc. quarterly revenues are --, which are smaller than ANI Pharmaceuticals, Inc. quarterly revenues of $227.8M. Allogene Therapeutics, Inc.'s net income of -$41.4M is lower than ANI Pharmaceuticals, Inc.'s net income of $24.1M. Notably, Allogene Therapeutics, Inc.'s price-to-earnings ratio is -- while ANI Pharmaceuticals, Inc.'s PE ratio is 50.74x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Allogene Therapeutics, Inc. is 2,442.58x versus 2.02x for ANI Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ALLOAllogene Therapeutics, Inc.2,442.58x -- -- -$41.4M ANIPANI Pharmaceuticals, Inc.2.02x 50.74x $227.8M $24.1M
-
Which has Higher Returns ALLO or PLX?
Protalix Biotherapeutics, Inc. has a net margin of -295454.55% compared to Allogene Therapeutics, Inc.'s net margin of 13.19%. Allogene Therapeutics, Inc.'s return on equity of -54.89% beat Protalix Biotherapeutics, Inc.'s return on equity of 12.06%.
Company Gross Margin Earnings Per Share Invested Capital ALLOAllogene Therapeutics, Inc.-- -$0.19 $400.5M PLXProtalix Biotherapeutics, Inc.53.37% $0.03 $61.1M -
What do Analysts Say About ALLO or PLX?
Allogene Therapeutics, Inc. has a consensus price target of $7.56, signalling upside risk potential of 425%. On the other hand Protalix Biotherapeutics, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 528.57%. Given that Protalix Biotherapeutics, Inc. has higher upside potential than Allogene Therapeutics, Inc., analysts believe Protalix Biotherapeutics, Inc. is more attractive than Allogene Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ALLOAllogene Therapeutics, Inc.9 2 0 PLXProtalix Biotherapeutics, Inc.1 0 0 -
Is ALLO or PLX More Risky?
Allogene Therapeutics, Inc. has a beta of 0.471, which suggesting that the stock is 52.924% less volatile than S&P 500. In comparison Protalix Biotherapeutics, Inc. has a beta of -0.248, suggesting its less volatile than the S&P 500 by 124.798%.
-
Which is a Better Dividend Stock ALLO or PLX?
Allogene Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Allogene Therapeutics, Inc. pays -- of its earnings as a dividend. Protalix Biotherapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ALLO or PLX?
Allogene Therapeutics, Inc. quarterly revenues are --, which are smaller than Protalix Biotherapeutics, Inc. quarterly revenues of $17.9M. Allogene Therapeutics, Inc.'s net income of -$41.4M is lower than Protalix Biotherapeutics, Inc.'s net income of $2.4M. Notably, Allogene Therapeutics, Inc.'s price-to-earnings ratio is -- while Protalix Biotherapeutics, Inc.'s PE ratio is 25.18x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Allogene Therapeutics, Inc. is 2,442.58x versus 2.23x for Protalix Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ALLOAllogene Therapeutics, Inc.2,442.58x -- -- -$41.4M PLXProtalix Biotherapeutics, Inc.2.23x 25.18x $17.9M $2.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Sell
44
PSTG alert for Dec 5
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 22.58% over the past day.
Buy
69
ASTS alert for Dec 5
AST Spacemobile, Inc. [ASTS] is up 18.25% over the past day.
